Reliance maps ₹1 trillion FMCG run-rate by FY30 as Karkinos clears 1 lakh HPV screenings
AGM blueprint targets doubling EBITDA in five years, with RCPL chasing ₹1 trillion in FY30 revenue and deeper bets on fresh produce, apparel and electronics retail. Healthcare arm Karkinos crosses 1 lakh HPV DNA screenings even as the stock trails 16.5% YTD.
What happened
Reliance Industries in focus after Karkinos Healthcare crossed 1 lakh HPV DNA screenings. AGM growth plans include doubling EBITDA in 5 years, ₹1 trillion FMCG
Key facts
- 1 lakh women screened
- 16.5% YTD share decline
- ₹1 trillion RCPL FY30 revenue target
- $125-150 bn exports by 2032
Why this matters
Karkinos hitting 1 lakh HPV screenings validates Reliance's healthcare optionality and opens M&A or partnership lanes in oncology diagnostics adjacent to the retail-pharmacy footprint.
What to watch
- HUL/Nestle/ITC volume growth prints — proxy for RCPL share gain
- Campa Cola market share in cola category (currently ~10%)
- JioMart + Reliance Retail SSSG re-acceleration
- Karkinos screening-to-revenue conversion metrics
- Any RIL AGM 2025 update on retail demerger/listing
- Track RCPL quarterly run-rate disclosures vs ₹20k cr FY25 base
- Watch for FMCG acquisition announcements (regional staples, personal care)
- Monitor Karkinos partnership with state govts for cervical cancer screening tenders
- Reliance Retail IPO timeline signals — key for re-rating